GLPwatch
Papers (10588)
Page 168 of 177, ranked by citation count.
- Dulaglutide-Associated Lichen Planus Pemphigoides.
- Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
- Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions.
- Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.
- [The role of obesity and weight reduction in obstructive sleep apnea].
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
- [Glucagon-like peptide-1 receptor agonists].
- No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study.
- Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.
- Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
- A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction.
- Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.
- Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.
- Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss.
- Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.
- A renal indication for semaglutide (Ozempic).
- GLP-1 receptor agonist suppresses fatty infiltration while improving range of motion and electromyographic function in a chronic rotator cuff tear rat model.
- Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.
- Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
- Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide.
- Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
- Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.
- Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.
- Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system.
- Targeting Cellulite as a Metabolic-Dermal Interface: Effects of Tirzepatide and a Multi-Pathway Topical Therapy (G21) in a 12-Month Observational Study.
- Noninsulin drugs for type 2 diabetes.
- Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association.
- [ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].
- Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.
- Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.
- Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.
- Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression.
- Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
- Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA).
- Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
- Tirzepatide data: safety always comes first!
- Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease.
- Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis.
- [Effects of glucagon-like peptide 1 and its receptor agonist - liraglutide on cardiovascular system].
- The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
- Meeting of the minds: Send your stories.
- Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL - 2024.
- Effects of GLP-1 Receptor Agonists on Psoriasis: An "Agent-Specific" Systematic Review of the Literature.
- GLP-1 Receptor Agonists and Fertility: What Is Known So Far?
- Short-term effect of tirzepatide on serum calcitonin in adults with obesity.
- Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?
- Evaluating the antidepressant effects of tirzepatide on unpredictable chronic mild stress-induced depression in Swiss Albino mice.
- [Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes].
- [Technological Innovations in Diabetes Therapy].
- Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.
- Functional Performance of Silk Nanoparticles for Oral Drug Delivery.
- Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.
- GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.
- Synthesis, Characterization, and Antidiabetic Evaluation of Sequence-Modified Liraglutide Analogs in a Drosophila melanogaster Model.
- Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes.
- Pharmacological progress in obesity: tirzepatide's rising advantage over semaglutide.
- Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.
- Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.
- [In Process Citation].